CGEM
Price
$14.91
Change
+$0.02 (+0.13%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
958.24M
14 days until earnings call
Intraday BUY SELL Signals
PRAX
Price
$258.83
Change
+$2.36 (+0.92%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
7.16B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CGEM vs PRAX

CGEM vs PRAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CGEM vs. PRAX commentary
Oct 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEM is a Hold and PRAX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CGEM with price predictions
Oct 21, 2026

CGEM's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for CGEM moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 20 of the 23 cases the stock moved higher. This puts the odds of a move higher at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 68 cases where CGEM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for CGEM just turned positive on October 20, 2026. Looking at past instances where CGEM's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.

Following a +6.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEM advanced for three days, in 206 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

CGEM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGEM as a result. In 82 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

CGEM moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CGEM crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for CGEM entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.978) is normal, around the industry mean (2.988). P/E Ratio (-4.788) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. CGEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PRAX with price predictions
Oct 21, 2026

PRAX sees its Stochastic Oscillator climbs out of oversold territory

On October 20, 2026, the Stochastic Oscillator for PRAX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 48 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PRAX's RSI Oscillator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for PRAX just turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.

Following a +9.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 258 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

PRAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for PRAX crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for PRAX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.340) is normal, around the industry mean (2.988). P/E Ratio (-19.789) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
PRAX: Fundamental Ratings
PRAX
OUTLOOK RATING
1..100
62
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
24
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CGEMPRAX
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 9 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
COMPARISON
Comparison
Oct 22, 2026
Stock price -- (CGEM: $14.89 vs. PRAX: $256.47)
Brand notoriety: CGEM and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEM: 65% vs. PRAX: 99%
Market capitalization -- CGEM: $958.24M vs. PRAX: $7.16B
CGEM [@Biotechnology] is valued at $958.24M. PRAX’s [@Biotechnology] market capitalization is $7.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEM’s FA Score shows that 2 FA rating(s) are green while PRAX’s FA Score has 2 green FA rating(s).

  • CGEM’s FA Score: 2 green, 3 red.
  • PRAX’s FA Score: 2 green, 3 red.
According to our system of comparison, both CGEM and PRAX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEM’s TA Score shows that 5 TA indicator(s) are bullish while PRAX’s TA Score has 5 bullish TA indicator(s).

  • CGEM’s TA Score: 5 bullish, 5 bearish.
  • PRAX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PRAX is a better buy in the short-term than CGEM.

Price Growth

CGEM (@Biotechnology) experienced а +9.16% price change this week, while PRAX (@Biotechnology) price change was +7.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -15.52%.

Reported Earning Dates

CGEM is expected to report earnings on Nov 05, 2026.

PRAX is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CGEM
Daily Signal:
Gain/Loss:
PRAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CGEM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEM has been loosely correlated with CABA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEM jumps, then CABA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEM
1D Price
Change %
CGEM100%
+0.40%
CABA - CGEM
49%
Loosely correlated
-4.35%
RAPP - CGEM
49%
Loosely correlated
-14.67%
RCKT - CGEM
48%
Loosely correlated
-5.98%
RLAY - CGEM
47%
Loosely correlated
-0.22%
PRME - CGEM
46%
Loosely correlated
-2.81%
More

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with FULC. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
-3.03%
FULC - PRAX
44%
Loosely correlated
-0.54%
VERA - PRAX
41%
Loosely correlated
+3.79%
BEAM - PRAX
40%
Loosely correlated
-0.36%
PTGX - PRAX
39%
Loosely correlated
+0.07%
CGEM - PRAX
38%
Loosely correlated
+0.40%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ROCQ54.810.46
+0.84%
JPMorgan Nasdaq Equity Premium Yield ETF (ROCQ)
XBOC36.750.13
+0.35%
Innovator U.S. Equity Accelerated 9 Buffer ETF - October (XBOC)
BSMV20.180.05
+0.24%
Invesco BulletShares 2031 Municipal Bond ETF (BSMV)
WMTI20.30-0.01
-0.07%
REX WMT Growth & Income ETF
PFF28.82-0.05
-0.17%
iShares Preferred & Income Securities ETF (PFF)